Jeremy A Rassen Scd

List of Publications by Citations

69 papers	4,935 citations	35 h-index	70 g-index
77 ext. papers	5,939 ext. citations	5.1 avg, IF	5.54 L-index

#	Paper	IF	Citations
69	High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. *Epidemiology*, **2009**, 20, 512-22	3.1	712
68	The comparative safety of analgesics in older adults with arthritis. *Archives of Internal Medicine*, **2010**, 170, 1968-76		282
67	Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. *Science*, **2020**, 370,	33.3	261
66	One-to-many propensity score matching in cohort studies. *Pharmacoepidemiology and Drug Safety*, **2012**, 21 Suppl 2, 69-80	2.6	253
65	Confounding control in healthcare database research: challenges and potential approaches. *Medical Care*, **2010**, 48, S114-20	3.1	237
64	Instrumental variable methods in comparative safety and effectiveness research. *Pharmacoepidemiology and Drug Safety*, **2010**, 19, 537-54	2.6	229
63	Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. *Circulation*, **2009**, 120, 2322-9	16.7	177
62	The comparative safety of opioids for nonmalignant pain in older adults. *Archives of Internal Medicine*, **2010**, 170, 1979-86		172
61	Effects of adjusting for instrumental variables on bias and precision of effect estimates. *American Journal of Epidemiology*, **2011**, 174, 1213-22	3.8	163
60	Metrics for covariate balance in cohort studies of causal effects. *Statistics in Medicine*, **2014**, 33, 1685-99	2.3	145
59	Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. *Clinical Pharmacology and Therapeutics*, **2011**, 90, 777-90	6.1	137
58	Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. *European Heart Journal*, **2012**, 33, 1893-901	9.5	137
57	Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. *American Journal of Epidemiology*, **2011**, 173, 1404-13	3.8	132
56	Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. *Journal of Clinical Epidemiology*, **2009**, 62, 1226-32	5.7	123
55	Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection. *JAMA Internal Medicine*, **2021**, 181, 672-679	11.5	120
54	Instrumental variable analysis for estimation of treatment effects with dichotomous outcomes. *American Journal of Epidemiology*, **2009**, 169, 273-84	3.8	114
53	Matching by propensity score in cohort studies with three treatment groups. *Epidemiology*, **2013**, 24, 401-9	3.1	103

52	Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. *Journal of Clinical Epidemiology*, **2009**, 62, 1233-41	5.7	91
51	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. *Pharmacoepidemiology and Drug Safety*, **2017**, 26, 1018-1032	2.6	78
50	Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. *Arthritis and Rheumatism*, **2006**, 54, 3390-8		74
49	Cardiovascular risk in rheumatoid arthritis: comparing TNF-□blockade with nonbiologic DMARDs. *American Journal of Medicine*, **2013**, 126, 730.e9-730.e17	2.4	72
48	Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. *Pharmacoepidemiology and Drug Safety*, **2012**, 21 Suppl 1, 41-9	2.6	70
47	Plasmode simulation for the evaluation of pharmacoepidemiologic methods in complex healthcare databases. *Computational Statistics and Data Analysis*, **2014**, 72, 219-226	1.6	60
46	Graphical Depiction of Longitudinal Study Designs in Health Care Databases. *Annals of Internal Medicine*, **2019**, 170, 398-406	8	58
45	Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. *Pharmacoepidemiology and Drug Safety*, **2012**, 21, 697-709	2.6	53
44	Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. *BMJ, The*, **2013**, 347, f5416	5.9	52
43	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. *Value in Health*, **2017**, 20, 1009-1022	3.3	47
42	Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. *European Heart Journal*, **2010**, 31, 561-72	9.5	47
41	Evaluating the validity of an instrumental variable study of neuroleptics: can between-physician differences in prescribing patterns be used to estimate treatment effects?. *Medical Care*, **2007**, 45, S116-22	3.1	45
40	Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. *Annals of the Rheumatic Diseases*, **2013**, 72, 1813-8	2.4	43
39	Confounding adjustment in comparative effectiveness research conducted within distributed research networks. *Medical Care*, **2013**, 51, S4-10	3.1	43
38	Measuring prevalence and incidence of chronic conditions in claims and electronic health record databases. *Clinical Epidemiology*, **2019**, 11, 1-15	5.9	40
37	Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. *Clinical Pharmacology and Therapeutics*, **2012**, 92, 80-6	6.1	39
36	Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases. *Pharmacoepidemiology and Drug Safety*, **2010**, 19, 848-57	2.6	37
35	Variable Selection for Confounding Adjustment in High-dimensional Covariate Spaces When Analyzing Healthcare Databases. *Epidemiology*, **2017**, 28, 237-248	3.1	36

34	Design considerations in an active medical product safety monitoring system. *Pharmacoepidemiology and Drug Safety*, **2012**, 21 Suppl 1, 32-40	2.6	35
33	High-dimensional propensity score algorithm in comparative effectiveness research with time-varying interventions. *Statistics in Medicine*, **2015**, 34, 753-81	2.3	31
32	Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. *Pharmacoepidemiology and Drug Safety*, **2011**, 20, 1199-209	2.6	28
31	Comparative effectiveness of preventative therapy for venous thromboembolism after coronary artery bypass graft surgery. *Circulation: Cardiovascular Interventions*, **2012**, 5, 590-6	6	28
30	Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. *Epidemiology*, **2012**, 23, 238-46	3.1	27
29	Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics. *Medical Care*, **2010**, 48, S83-9	3.1	25
28	Effects of expanding the look-back period to all available data in the assessment of covariates. *Pharmacoepidemiology and Drug Safety*, **2017**, 26, 890-899	2.6	24
27	Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. *BMC Medical Research Methodology*, **2012**, 12, 180	4.7	24
26	Diagnosis-wide analysis of COVID-19 complications: an exposure-crossover study. *Cmaj*, **2021**, 193, E10-E18	3.5	22
25	A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. *Pharmacoepidemiology and Drug Safety*, **2014**, 23, 619-27	2.6	20
24	Myers et al. Respond to "Understanding Bias Amplification". *American Journal of Epidemiology*, **2011**, 174, 1228-1229	3.8	20
23	Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic "matrix design". *Pharmacoepidemiology and Drug Safety*, **2011**, 20, 675-83	2.6	19
22	Prospective cohort studies of newly marketed medications: using covariate data to inform the design of large-scale studies. *Epidemiology*, **2014**, 25, 126-33	3.1	14
21	Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. *Drug Safety*, **2014**, 37, 151-61	5.1	13
20	Adjuvant vancomycin for antibiotic prophylaxis and risk of Clostridium difficile infection after coronary artery bypass graft surgery. *Journal of Thoracic and Cardiovascular Surgery*, **2013**, 146, 472-8	1.5	10
19	Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples. *Drug Safety*, **2012**, 35, 407-16	5.1	10
18	An event-based approach for comparing the performance of methods for prospective medical product monitoring. *Pharmacoepidemiology and Drug Safety*, **2012**, 21, 631-9	2.6	10
17	Confronting "confounding by health system use" in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment. *Pharmacoepidemiology and Drug Safety*, **2012**, 21 Suppl 2, 90-8	2.6	10

16	Effectiveness of the Single-Dose Ad26.COV2.S COVID Vaccine		9
15	Selective Serotonin Reuptake Inhibitor Use and Perioperative Bleeding and Mortality in Patients Undergoing Coronary Artery Bypass Grafting: A Cohort Study. *Drug Safety*, **2015**, 38, 1075-82	5.1	7
14	Real-world evidence of bariatric surgery and cardiovascular benefits using electronic health records data: A lesson in bias. *Diabetes, Obesity and Metabolism*, **2021**, 23, 1453-1462	6.7	7
13	Optimal matching ratios in drug safety surveillance. *Epidemiology*, **2014**, 25, 772-3	3.1	6
12	Re: Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to electronic medical records. *Pharmacoepidemiology and Drug Safety*, **2011**, 20, 1110-1; author reply 1112	2.6	6
11	Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes. *Journal of Managed Care & Specialty Pharmacy*, **2019**, 25, 1442-1452	1.9	6
10	Incorporating linked healthcare claims to improve confounding control in a study of in-hospital medication use. *Drug Safety*, **2015**, 38, 589-600	5.1	5
9	Renin-Angiotensin-Aldosterone-System inhibitor use in patients with COVID-19 infection and prevention of serious events: a cohort study in commercially insured patients in the US		5
8	COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. *PLoS ONE*, **2021**, 16, e0248128	3.7	4
7	Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 816-828	6.1	3
6	Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge.. *JAMA Network Open*, **2022**, 5, e222959	10.4	3
5	The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications. *Clinical Pharmacology and Therapeutics*, **2021**, 111, 135	6.1	2
4	Single-arm oncology trials and the nature of external controls arms. *Journal of Comparative Effectiveness Research*, **2021**, 10, 1052-1066	2.1	2
3	Using Real-World Data to Predict Clinical and Economic Benefits of a Future Drug Based on its Target Product Profile. *Drugs - Real World Outcomes*, **2020**, 7, 221-227	2.2	1
2	Response to commentary by Marcus and Gibbons. *Pharmacoepidemiology and Drug Safety*, **2012**, 21, 713	2.6	
1	Reply to the Letter by Arterburn D. et al. ("Bias in EHR-based studies: Seeing the Forest for the Trees"). *Diabetes, Obesity and Metabolism*, **2021**, 23, 1694-1695	6.7	